ACF Investors

Great news coming from our portfolio company OTCX, as they announce a strategic partnership with BlackRock's Aladdin!

Livestock and equine wound care has long relied on antibiotics and cloth bandages - an approach that often falls short in harsh agricultural environments where slurry and bacteria can quickly compromise treatment. NoBACZ Healthcare is transforming this with its patented ‘liquid bandage’ technology, developed at the University of Cambridge. Applied as a gel, dip, or spray, it forms an instant waterproof and biodegradable barrier that protects wounds, reduces infection risk, and enables faster healing - all without antibiotics. Today, NoBACZ announced its £4.8m raise to accelerate the global commercialisation of its technology. We are proud to have participated alongside The Yield Lab, Adjuvo, University of Cambridge, Parkwalk Advisors, The FSE Group, and Cambridge Enterprise Ventures. Congratulations to Jonathan Powell, Nuno Faria, and the entire NoBACZ team. We look forward to supporting you as you redefine wound care in veterinary healthcare… and beyond. Check out the full story in Sky News here: https://shorturl.at/iyLy4 #VentureCapital #Fundraising #VC #Innovation #Growth

We are proud to share that ACF Investors has been shortlisted for the prestigious GP Bullhound’s Allstars Awards in the ‘VC of the Year’ category These awards are among the most respected in the European investment community, celebrating the people and firms helping to shape innovation and growth across the ecosystem. It’s an honour to be recognised alongside so many outstanding firms, and we would like to extend our congratulations to all of this year’s nominees. You can view the full shortlist here: https://shorturl.at/E2XRE #VC #VentureCapital

We’re excited to announce a significant milestone from our portfolio company Veremark, which has announced the acquisition of Agenda Screening Services Ltd. This acquisition combines Veremark’s innovative technology and global reach with Agenda’s  25+ years of trusted expertise in flexible background screening solutions. The move solidifies Veremark’s position as a leader in global background screening and credential verification. This partnership will expand capabilities across Europe, deepen sector knowledge, and accelerate progress toward building the world’s smartest background screening solution. Congratulations to Daniel Callaghan and the entire team on this achievement. #VentureCapital #VC

Neurovalens is a pioneering medical device company which specialises in leveraging the power of neuroscience and advanced technology to address a variety of global health challenges, including insomnia, anxiety and post-traumatic stress disorder (PTSD). Today, the company has announced its £6m investment round, which we are proud to have participated in alongside  Investment Fund for Northern Ireland (managed by Clarendon Fund Managers), Whiterock ’s Growth Capital Fund, IQ Capital and Innovation Ulster Ltd. The investment round will support Neurovalens’ commercial expansion across the US and global healthcare markets, advance its regulatory pipeline, and accelerate sales of its FDA-cleared devices. Congratulations to Jason McKeown and the entire team. We look forward to supporting your next stage of growth. Check out the full story in UKTN here: https://lnkd.in/gYguQG7e #VentureCapital #Fundraising #VC #Innovation #Growth

We were delighted to have attended the UK Business Angels Association Awards last week and celebrate the brilliant individuals and teams driving innovation and investment across the UK’s early-stage ecosystem. Our Managing Partner, Timothy Mills, had the privilege of presenting the Angel of the Year award to this year’s deserving recipients, Amir Nooriala and Claire Valoti. Their contributions to the angel investing community have been truly outstanding, and we extend our warmest congratulations to them both. Thank you to the UKBAA for a wonderful evening, and we look forward to next time. #UKBAAAwards #VentureCapital

Biopharma companies need objective data to effectively establish baseline information on how a drug is engaging with the region of the brain it is targeting. Yet, most studies still rely on traditional pen and paper assessments, which lack real insight into underlying brain activity. Cumulus Neuroscience addresses this with its flagship EEG headset, used to scan and analyse the brain, assessing functions such as cognition, mood and language. Their solution empowers clinicians and researchers to gather rich brain data quickly, even remotely in patients’ homes. Today, Cumulus Neuroscience announced its £3.25m raise, which we are proud to have participated in, alongside Whiterock , The Investment Fund for Northern Ireland (managed by Clarendon Fund Managers), and Co-Fund NI. Congratulations to Tina Sampath and the entire team. We look forward to supporting your next stage of growth. Check out the full story in Tech.eu here: https://lnkd.in/ewpQcx4V #VentureCapital #Fundraising #VC #Innovation #Growth

When assessing income and employment, lenders still rely heavily on legacy systems, which are slow, error-prone, and often incomplete, preventing many people from accessing credit. Teal solves this by providing lenders with real-time, verified income and employment data, creating a more transparent, inclusive, and user-centric credit ecosystem that allows users to access credit that works for them. This week, Teal announced its £1.4m funding round, which we are proud to have participated in alongside Passion Capital, Kfund and prominent angel investors from notable fintechs such as Plaid and Checkout.com. The funding will be used to bring instant income and employment verification to millions across the UK. Congratulations to Michael Hart, André Saavedra Pinto and the entire team. We look forward to supporting your next stage of growth. Check out the full story in UKTN here: https://shorturl.at/Cwobl #VentureCapital #Fundraising #VC #Innovation #Growth

Successive governments have rightly identified #startups as a key factor in solving the UK’s long-term growth and productivity problem. However, despite various incentives, we’re not seeing an increase in people building scalable businesses. This is because the UK’s current attitude towards risk, and the value it delivers, is holding entrepreneurs back. Our Managing Partner, Timothy Mills, discussed the UK’s secret startup problem with UKTN. Tim looks at what is driving this cautious attitude, the effect it is having on UK businesses, and how the government can provide #entrepreneurs with the confidence they need to think big and take a risk, vital in ensuring that the UK remains an attractive place to start and grow the next generation of world-leading businesses. Read the full piece in UKTN here: https://lnkd.in/dRYrcD_6 #Investment #VentureCapital #Growth #VC

Startups has published comprehensive new guides on Venture Capital and Seed funding - and it is great to see ACF Investors partner, George Whitehead, contributing his expert insight. George shares valuable advice for founders on how to navigate the fundraising journey - from what VCs look for in a startup to the key metrics that matter most during evaluation. These are accessible and informative guides for anyone first interested in the VC or seed funding landscape, and we are proud to be involved. Read the full piece by Emily Clark on Seed funding here: https://shorturl.at/7jZRY, and Venture Capital here: https://shorturl.at/0B58t #Innovation #VentureCapital #VC #Startups #SeedFunding #Investment